The M. D. Anderson Myeloma SPORE Career Development Program (CDP) has the following objectives: 1. Recruit and train physicians, scientists, and senior postdoctoral fellows to become outstanding translational investigators in myeloma research. 2. Establish a Structure for Project Identification and Selection. Publicize the availability of start-up funding for pilot projects in myeloma translational research. Develop a peer-review mechanism to select competing proposals for funding using internal and external reviewers. Develop specific criteria for selection of projects for funding for use by the reviewers. The SPORE Administrative Core plays a major role in this. Identify projects that are innovative and have significant potential for improving treatment outcome of myeloma. The expertise of SPORE Pis, Project Leaders, Co-Investigators, and the scientific advisory board will be sought to achieve this goal. 3. Provide funding, resources, and encourage SPORE Collaborations. Provide development funding (usually in the amount of-$50,000) for projects in the M. D. Anderson Myeloma SPORE and for scientists at other institutions outside the SPORE environment. Encourage collaborations among scientists in the SPORE and with scientists outside the SPORE environment that will help investigators reach their objectives. Connect young investigators with other myeloma basic and clinical investigators at M. D. Anderson and at other SPORE institutions. The SPORE PI and Co-PI will work with investigators to define translational research goals and steps required to effectively and rapidly translate the research into application in humans. The CDP will facilitate access to SPORE Cores needed to reach these goals - Myeloma Tissue, Clinical Trials, Animal Models, Bioinformatics and Biostatistics, and GMP laboratory Cores. 4. Provide Mentorship for Career Development Awardees. Develop a mechanism for closely mentoring and monitoring the work ofthe Career Development Awardees to help achieve their translational research goals. Require Career Developmental Project investigators to give official presentations of their work at the regular monthly SPORE meetings as well as annual written reports. Provide expert mentors in myeloma translational research for the Career Development Projects. Review and help Career Development Project Investigators prepare their results for presentation and encourage presentation at inter-SPORE meetings, such as at the annual SPORE meeting. 5. Provide Assistance and Guidance For Obtaining Independent Peer Reviewed Funding. Require, with assistance, preparation of other peer-reviewed funding applications, such as R21 and Foundation grants, and help with grant draft review, and provide letters of support for these applications.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Glitza, Isabella C; Lu, Gary; Shah, Rupin et al. (2015) Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma. Leuk Lymphoma 56:602-7
Wen, Jianguo; Tao, Wenjing; Kuiatse, Isere et al. (2015) Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions. Int J Cancer 136:991-1002
Hong, Bangxing; Li, Haiyan; Zhang, Mingjun et al. (2015) p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion. Int J Cancer 136:34-43
Shi, Qiuling; Wang, Xin Shelley; Li, Guojun et al. (2015) Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. Cancer 121:1138-46
Wang, Xin Shelley; Shi, Qiuling; Williams, Loretta A et al. (2015) Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leuk Lymphoma 56:1335-41
Parmar, S; Kongtim, P; Champlin, R et al. (2014) Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. Bone Marrow Transplant 49:1036-41
Chen, Zheng; Orlowski, Robert Z; Wang, Michael et al. (2014) Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood 123:2204-8
San-Miguel, Jesús; Bladé, Joan; Shpilberg, Ofer et al. (2014) Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 123:4136-42
Srkalovic, Gordan; Hussein, Mohamad A; Hoering, Antje et al. (2014) A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. Cancer Med 3:1275-83
Ocio, Enrique M; Mitsiades, Constantine S; Orlowski, Robert Z et al. (2014) Future agents and treatment directions in multiple myeloma. Expert Rev Hematol 7:127-41

Showing the most recent 10 out of 79 publications